PRINCETON, N.J., May 29, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, and inVentiv Health Clinical, a leading global clinical research organization (CRO), announced today that they have entered into a master services agreement for the clinical development of certain immunotherapy product candidates in Advaxis's proprietary pipeline. The agreement is global and will focus initially on Advaxis's lead immunotherapy for cervical cancer, ADXS-HPV.
Under the terms of the agreement inVentiv can provide Advaxis
with full CRO services to execute clinical studies for the current Advaxis
cancer immunotherapy product candidates including ADXS-HPV for cervical cancer, and other HPV- associated cancer; ADXS-cHER2 for pediatric osteosarcoma and other HER2 over-expressing cancer and ADXS-PSA for prostate cancer. In addition, pending regulatory approval, Advaxis
can leverage inVentiv's significant commercialization capabilities in select countries, should it seek to do so.
inVentiv will work with Advaxis
to develop clinical study protocols and will serve as the CRO on the planned registrational trials that will evaluate the safety and efficacy of ADXS-HPV in women with recurrent cervical cancer. In addition, inVentiv will provide feasibility and study start-up activities for the planned clinical development of ADXS-cHER2 in pediatric osteosarcoma.
"We are extremely happy to be collaborating with Advaxis
in advancing Advaxis's
platform of cancer immunotherapies," said Greg Skalicky
, Chief Commercial Officer, inVentiv Health Clinical. "By combining the fully-integrated research and development capabilities of Advaxis
with inVentiv's broad clinical development and commercial expertise, we are moving well beyond traditional outsourced services and into the realm of a true strategic partnership."
"After an extensive global review of potential clinical research organizations, we selected the broad-scale inVentiv platform as an important differentiator for our program," said Daniel O'Connor
, President and CEO of Advaxis
. "This agreement spans clinical development, as well as potential commercial support for our cancer immunotherapy product candidates. As a next-generation CRO, inVentiv is able to work across the full development life cycle of each of our immunotherapy product candidates."About inVentiv Health Clinical
inVentiv Health Clinical is a next generation CRO. We take a patient-centric approach and apply smarter, fresher thinking to go well beyond traditional outsourced services. We are a leading provider of global drug development services to the biopharmaceutical industry, offering therapeutically specialized capabilities for phase I-IV clinical development, bioanalytical services, and strategic resourcing from a single clinical professional to an entire functional team. As part of inVentiv Health, we are the only company in the world that can both develop and fully commercialize products for the life sciences industry. Learn how our clinical, commercial and consulting services support the entire product lifecycle. www.inventivhealthclinical.comAbout Advaxis, Inc.Advaxis
is a clinical-stage biotechnology company developing multiple cancer immunotherapies based on its proprietary platform that is being investigated for redirecting the immune system to kill cancer. The Advaxis
technology, using bioengineered live attenuated bacteria, is the only cancer immunotherapy shown to actively suppress Tregs and MSDCs, components in the cancer microenvironment that are believed to contribute to tumor growth and protect it from immunologic attack. Advaxis's
lead immunotherapy candidate, ADXS-HPV, is being investigated for targeting human papillomavirus (HPV)-associated cancers and is in clinical trials for three indications: Phase 2 in invasive cervical cancer, Phase 1/2 in head and neck cancer, and Phase 1/2 in anal cancer. The FDA
has granted Advaxis Orphan Drug status for each of these three indications. Advaxis
plans to initiate a registrational clinical program for cervical cancer in 2014 and has established licensing partners in India
for commercialization in those regions.Advaxis
is also developing, ADXS-cHER2, to target the HER2 receptor, which is overexpressed in certain solid-tumor cancers, including pediatric bone cancer (or osteosarcoma), breast cancer, and gastric cancer. Advaxis
is developing ADXS-cHER2 for both human and animal-health, and interim findings in an ongoing clinical study in canine osteosarcoma, an excellent model for human bone cancer, have shown clinical benefits. Further confirmatory studies are planned. Advaxis
is pursuing a clinical program in pediatric osteosarcoma and has licensed ADXS-cHER2 and three other non-specified immunotherapy constructs to a major animal-health company.
For more information please visit www.advaxis.com
or connect with us on
Google+: https://plus.google.com/b/115126287957745987074/115126287957745987074/postsForward-Looking Statements
This news release contains forward-looking statements, including, but not limited to: statements regarding Advaxis'
ability to develop the next generation of cancer immunotherapies; the safety and efficacy of Advaxis'
proprietary immunotherapy, ADXS-HPV; whether Advaxis
immunotherapy candidates can redirect the immune response to the bacterium to cancers. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis'SEC
filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2013
, which is available at http://www.sec.gov
undertakes no obligation to publicly release the result of any revision to these forward-looking statements, which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
CONTACT: Advaxis Contact:
Senior Director of Investor Relations and Corporate Communications
Tiberend Strategic Advisors, Inc.Amy S. Wheelerawheeler@tiberend.com
Vice President, Marketing & Communication